Blood Res.  2015 Mar;50(1):51-53. 10.5045/br.2015.50.1.51.

HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT

• Gu HR
• Shin DY
• Choi HS
• Moon CH
• Park SC
• Kang HJ

• KMID: 1787913
• DOI: http://doi.org/10.5045/br.2015.50.1.51

Abstract

Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.

Keyword

HBV reactivation; Multiple myeloma; Transplantation; Prednisolone; Chemotherapy

MeSH Terms

Drug Therapy
Drug Therapy, Combination
Hematopoietic Stem Cell Transplantation
Hepatitis B
Hepatitis B virus
Humans
Korea
Lymphoma
Multiple Myeloma*
Prednisolone*
Transplantation
Prednisolone

Figure

• 

  Fig. 1 Changes in the liver function panel after entecavir treatment.

Reference

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507–539. PMID: 17256718.

2. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009; 27:605–611. PMID: 19075267.

3. Chung SM, Sohn JH, Kim TY, et al. Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B. Korean J Gastroenterol. 2010; 55:266–269. PMID: 20389182.

4. Kim H, Shin AR, Chung HH, et al. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med. 2013; 28:413–419. PMID: 23864799.

5. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202:192–201. PMID: 20533878.

6. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68:105–112. PMID: 1054319.

7. Kim MK, Ahn JH, Kim SB, et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med. 2007; 22:237–243. PMID: 18309681.

8. Senecal D, Pichon E, Dubois F, Delain M, Linassier C, Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant. 1999; 24:1243–1244. PMID: 10642815.

9. Goyama S, Kanda Y, Nannya Y, et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma. 2002; 43:2159–2163. PMID: 12533042.

10. Uhm JE, Kim K, Lim TK, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13:463–468. PMID: 17382252.

11. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988; 167:630–633. PMID: 3201757.